<<

. 4
( 4 .)



97. Snowden W, Shortino D, Klein A, et al. Development of amprenavir resistance in NRTI-experienced patients: alternative mechanisms and correlation with baseline
resistance to concomitant NRTIs. Antivir Ther 2000, 5 (Supplement 3):84.
98. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
AIDS 2004; 18: 1787-94. http://amedeo.com/lit.php?id=15316339
99. Shulman NS, Hughes M, MA Winters MA, et al. d4T virtual phenotype can predict virological response to d4T monotherapy after AZT treatment, but not at the current
cutoff. Antiviral Therapy 2004; 9:S132, Abstract 118. http://www.natap.org/2004/HIVDRW/hivdrw_16.htm
Tural C, Ruiz L, Holtzer C, et al. Utility of HIV genotyping and clinical expert advice - The Havana trial. Abstract 434, 8th CROI 2001, Chicago, USA.
100.
101. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in HIV type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
Antimicrob Agents Chemother 1997, 41:1094-1098. http://amedeo.com/lit.php?id=9145875
102. US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2004. Available at:
http://aidsinfo.nih.gov/guidelines/adult/AA_032304.html
103. Valer L, De Mendoza C, De Requena DG, et al. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002;
16:1964-6.
Van der Horst C, Quinn JB, Hinkle J, et al. Predictors of virologic failure in HIV-infected adults on a stable lamivudine HAART regimen. Abstract H21050, 42nd ICAAC
104.
2003, San Diego, USA.
105. Van de Vijver DAMC, Wensing AMJ, Angarano G, et al, on behalf of the SPREAD Programme. The calculated genetic barrier for drug resistance mutations in six
different non-B subtypes and two CRFs in a large European dataset is largely similar to subtype B. Antivir Ther. 2004;9:S98.
http://www.aegis.com/conferences/13thHIVDrugResWkshop/87.html
106. Vandamme AM, Van Laethem, de Clercq E. Managing resistance to anti-HIV drugs. Drugs 1999, 57:337-361. http://amedeo.com/lit.php?id=10193687
107. Wensing AMJ, van der Vijver DAMC, Asjo B, et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10 % of
the patients carry primary drug resistance: The Catch-study. Abstract LB1, 2nd IAS 2003, Paris, France.
Whitcomb J, Deeks S, Huang W, et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1-infected patients. Abstract 234, 7th
108.
CROI 2000 San Francisco, USA.
109. Wilson JW. Update on antiretroviral drug resistance testing: Combining laboratory technology with patient care. AIDS Read 2003, 13:25-38.
http://www.medscape.com/viewarticle/448717
110. Winters MA, Shafer RW, Jellinger RA, et al. HIV type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine
monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997, 41:757-762. http://amedeo.com/lit.php?id=9087484
Xu L, Pozniak A, Wildfire A, et al. Evolution of HR1 and HR2 Mutations in HIV-1 gp41 Associated with Long-term Enfuvirtide Therapy. Abstract 659, 11th CROI 2004,
111.
San Francisco, USA. http://64.251.206.31/2004/AbstractSearch/AbstractSearch.aspx

<<

. 4
( 4 .)